{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:12:33Z","timestamp":1789056753161,"version":"build-2803163510"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Androgen deprivation therapy (ADT), widely used in men with advanced prostate cancer, has been implicated in cognitive decline. Evidence from Western cohorts remains inconsistent, with limited long-term and India-specific data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a prospective, observational case\u2013control study between July 2021 and December 2024 with a minimum 36-month follow-up. Men initiating ADT (luteinizing hormone-releasing hormone analogues or bilateral orchidectomy) were compared with a control cohort (benign prostatic hyperplasia or postradical prostatectomy without ADT). Groups were matched for age, baseline Addenbrooke\u2019s cognitive examination III (ACE-III) score, G8 frailty score, and gait speed. Cognitive assessments were performed every 6 months using the culturally validated Hindi ACE-III tool. The primary outcome was the change in total ACEII score over 36 months; secondary outcomes included domain-wise changes and correlations with frailty and gait speed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Sixty men were enrolled (30 per group); 21 men received ADT, and 23 served as controls, completing follow-up. Over 36 months, both groups showed modest declines in cognition, with a mean decline of \u22122.30 \u00b1 1.13 for the ADT group and \u22121.87 \u00b1 1.62 for the control group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.638). Domain-wise changes (attention, memory, fluency, language, and visuospatial) were small and statistically similar. Stratified analyses by frailty (G8 \u2264 14 vs. &gt;14) and gait speed (\u22640.6 m\/s vs. &gt;0.6 m\/s) revealed parallel trajectories in both groups, with no effect of ADT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this 36-month prospective study using a culturally validated tool, ADT was not associated with accelerated global or domain-specific cognitive decline compared to a matched cohort without ADT. These findings suggest that in appropriately selected patients, ADT can be administered without undue concern for disproportionate cognitive deterioration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/iju.iju_429_25","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T10:00:09Z","timestamp":1774692009000},"page":"133-138","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Androgen deprivation therapy and cognitive trajectories in Indian men: A 36-month prospective matched cohort analysis with Addenbrooke\u2019s cognitive examination-III"],"prefix":"10.4103","volume":"42","author":[{"given":"Gyvi","family":"Gaurav","sequence":"first","affiliation":[{"name":"Department of Urology, Precison Urology Hospital, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashikant","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Urology, Precison Urology Hospital, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya P. S.","family":"Sengar","sequence":"additional","affiliation":[{"name":"Department of Urology, Precison Urology Hospital, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Lohani","sequence":"additional","affiliation":[{"name":"Department of Urology, Precison Urology Hospital, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurodh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Urology, Precison Urology Hospital, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd","family":"Amir","sequence":"additional","affiliation":[{"name":"Department of Urology, Precison Urology Hospital, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"R1-20260330","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"key":"R2-20260330","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once-weekly alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"R3-20260330","first-page":"e4279","article-title":"Serum testosterone is inversely, and sex hormone-binding globulin directly, associated with all-cause mortality in men","volume":"105","author":"Yeap","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"R4-20260330","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1464-410X.2002.02917.x","article-title":"Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate:A randomized controlled trial","volume":"90","author":"Green","year":"2002","journal-title":"BJU Int"},{"key":"R5-20260330","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1200\/JCO.2010.30.8742","article-title":"Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer","volume":"28","author":"Alibhai","year":"2010","journal-title":"J Clin Oncol"},{"key":"R6-20260330","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1464-410X.2005.05565.x","article-title":"Does neoadjuvant hormone therapy for early prostate cancer affect cognition?Results from a pilot study","volume":"96","author":"Jenkins","year":"2005","journal-title":"BJU Int"},{"key":"R7-20260330","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1212\/01.wnl.0000434309.85312.19","article-title":"A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia","volume":"55","author":"Mathuranath","year":"2000","journal-title":"Neurology"},{"key":"R8-20260330","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy:ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"key":"R9-20260330","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/annonc\/mdu210","article-title":"Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients:An update on SIOG recommendations\u2020","volume":"26","author":"Decoster","year":"2015","journal-title":"Ann Oncol"},{"key":"R10-20260330","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jama.2010.1923","article-title":"Gait speed and survival in older adults","volume":"305","author":"Studenski","year":"2011","journal-title":"JAMA"},{"key":"R11-20260330","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","article-title":"Screening older cancer patients:First evaluation of the G-8 geriatric screening tool","volume":"23","author":"Bellera","year":"2012","journal-title":"Ann Oncol"},{"key":"R12-20260330","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.2013.51.1345","article-title":"Performance of two geriatric screening tools in older patients with cancer","volume":"32","author":"Kenis","year":"2014","journal-title":"J Clin Oncol"},{"key":"R13-20260330","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/arclin\/acaa013","article-title":"Dementia Diagnosis in Seven Languages:The Addenbrooke's Cognitive Examination-III in India","volume":"35","author":"Mekala","year":"2020","journal-title":"Arch Clin Neuropsychol"},{"key":"R14-20260330","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.cger.2013.07.002","article-title":"Normal cognitive aging","volume":"29","author":"Harada","year":"2013","journal-title":"Clin Geriatr Med"},{"key":"R15-20260330","first-page":"146","article-title":"An updated guide for sample size determination in the development and validation of a patient-reported outcome instrument using structural equation modeling:A review","volume":"16","author":"Arifin","year":"2021","journal-title":"J Taibah Univ Med Sci"},{"key":"R16-20260330","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1097\/01.ju.0000091640.59812.83","article-title":"The effects of androgen deprivation therapy on cognitive function in men with prostate cancer","volume":"170","author":"Cherrier","year":"2003","journal-title":"J Urol"},{"key":"R17-20260330","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1097\/01.ju.0000091640.59812.83","article-title":"The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer","volume":"170","author":"Cherrier","year":"2003","journal-title":"J Urol"},{"key":"R18-20260330","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/pon.1401","article-title":"Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer","volume":"18","author":"Cherrier","year":"2009","journal-title":"Psychooncology"},{"key":"R19-20260330","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/cncr.30320","article-title":"Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer","volume":"123","author":"Alibhai","year":"2017","journal-title":"Cancer"},{"issue":"(2)","key":"R20-20260330","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.critrevonc.2010.06.009","article-title":"Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer","author":"Mohile","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"R21-20260330","first-page":"2271","article-title":"Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer:A systematic review and meta-analysis","volume":"22","author":"McGinty","year":"2014","journal-title":"Support Care Cancer"},{"key":"R22-20260330","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.juro.2017.11.136","article-title":"Cognitive impairment in men with prostate cancer treated with androgen deprivation therapy:A systematic review and meta-analysis","volume":"199","author":"Sun","year":"2018","journal-title":"J Urol"},{"key":"R23-20260330","doi-asserted-by":"crossref","first-page":"7575","DOI":"10.1158\/1078-0432.CCR-04-0750","article-title":"Associations between serum testosterone fall and cognitive function in prostate cancer patients","volume":"10","author":"Salminen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R24-20260330","first-page":"888","article-title":"Androgen deprivation and cognition in prostate cancer","volume":"92","author":"Salminen","year":"2005","journal-title":"Br J Cancer"}],"container-title":["Indian Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/iju.iju_429_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:39:26Z","timestamp":1787837966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/iju.iju_429_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/iju.iju_429_25","relation":{},"ISSN":["0970-1591","1998-3824"],"issn-type":[{"value":"0970-1591","type":"print"},{"value":"1998-3824","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"2025-09-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}